DATA: 11 e 12 de março de 2022
Evento híbrido
Vagas limitadas: Vagas presenciais esgotadas
Endereço: Rua Prof. Daher Cutait, 69 – Bela Vista – São Paulo/SP
Apresentação: O curso aborda as diferentes facetas do cuidado de pacientes com neoplasias cutâneas a partir dos pilares que sustentam o cuidado centralizado no paciente, incluindo multidisciplinaridade, cooperação entre equipes e especialização.
Público-alvo: Dermatologistas, oncologistas clínicos, rádio oncologistas e cirurgiões oncológicos, além de acadêmicos e profissionais de saúde interessados no diagnóstico e no tratamento dos tumores cutâneos.
Comitê Científico: Núcleo de Oncologia Cutânea e Sarcomas do Hospital Sírio Libanês (Group of Cutaneous Malignancies and Sarcomas – Hospital Sírio Libanês) Centro de Oncologia do Hospital Sírio Libanês (Oncology Center – Hospital Sírio Libanês) Núcleo de Dermatologia do Hospital Sírio Libanês (Dermatology Service – Hospital Sírio Libanês
Valores Inscrição | |
Médicos | R$ 400,00 |
Profissionais da saúde não médicos e residentes | R$ 300,00 |
Sociedades Parceiras | R$ 320,00 |
Valores Inscrição | |
Médicos | R$ 400,00 |
Profissionais da saúde não médicos e residentes | R$ 300,00 |
Sociedades Parceiras | R$ 320,00 |
Acesso a LIVE
Exclusivo para participantes que selecionaram a opção online
PALESTRANTE INTERNACIONAL
Douglas Johnson
PALESTRANTE INTERNACIONAL
Sandra Wong
PALESTRANTE INTERNACIONAL
Vernon Sondak
PALESTRANTE INTERNACIONAL
Ashfaq Marghoob
PALESTRANTE INTERNACIONAL
Axel Hauschild
March, 11th (Friday)
Schedule subject to change and speakers confirmations |
|
07:30 a.m. – 08:20 a.m. |
Registration |
8:20 a.m. – 8:30 a.m. |
Opening |
Module: Initial steps Chairs: Vera de Barros e Mariana Petaccia |
|
8:30 a.m. – 8:45 a.m. |
Revisiting the evidences and alternatives for photoprotection |
8:45 a.m. – 9:00 a.m. |
The role of molecular pathology in differentiating pigmented lesions |
9:00 a.m. – 9:15 a.m. |
Dermatology insights: how not to miss the diagnosis of a melanoma? |
9:15 a.m. – 9:30 a.m. |
Integrating non-invasive techniques in the diagnosis of melanocytic lesions |
9:30 a.m.– 9:45 a.m. |
When a patient with skin cancer should seek genetic counseling? |
9:45 a.m. – 9:55 a.m. |
Discussion / Q&A |
9:55 a.m. – 10:15 a.m. |
Interval |
Module: Locorregional melanoma Chairs: Francisco Belfort e Eduardo Akaishi |
|
10:15 a.m. – 10:30 a.m. |
Tips and tricks for the appropriate management of lentigo |
10:30 a.m. – 10:45 a.m. |
Current adjuvant treatment options for high-risk stage II melanoma and future perspectives |
10:45 a.m. – 11:05 a.m. |
Debate: Now that we can treat high-risk stage II melanoma, should we perform SLN biopsy for this patient population? |
11:05 a.m. – 11:20 a.m. |
Sentinel LN biopsy in melanoma of the scalp/head and neck – controversies and recommendations |
11:20 a.m. – 11:35 a.m. |
Intralesional therapies in melanoma – updates and perspectives |
11:35 a.m. – 11:50 a.m. |
Stage III melanoma – shoot first and ask later? |
11:50 a.m. – 12:00 p.m. |
Discussion/ Q&A |
12:00 p.m. – 12:45:00 p.m. |
Satellite Symposium MERCK & PFIZER |
12:45 p.m. – 1:30 p.m. |
Satellite Symposium MSD* |
1:30 p.m. – 2:00 p.m. |
Interval |
Plenary Session – Day 01 Chairs: Marina Sahade e José Sanches |
|
2:00 p.m. – 2:20 p.m. |
Plenary 1 - Melanoma screening status – are we overdiagnosing in situ melanoma? |
2:20 p.m. – 2:40 p.m. |
Plenary 2 - Dermoscopy to aid in early melanoma identification: the yin-yang |
2:40 p.m. – 3:00 p.m. |
Plenary 3 - Dermoscopy algorithms in challenging skin tumors – a critical analysis |
3:00 p.m. – 3:20 p.m. |
Clinical conundrum: Treatment duration in patients with advanced cutaneous malignancies receiving ICP - does one size fit all? |
3:20 p.m. – 3:30 p.m. |
Roundtable and Q&A |
Module: Advanced melanoma Chairs: Rodrigo Munhoz and Frederico Teixeira Jr. |
|
3:30 p.m. – 3:45 p.m. |
Current status of the first-line treatment in advanced melanoma |
3:45 p.m. – 4:00 p.m. |
Optimizing the benefit from ICP: DOs and DON’Ts |
4:00 p.m. – 4:15 p.m. |
Debate: oligometastatic melanoma – surgery first vs systemic treatment first |
4:15 p.m. – 4:30 p.m. |
Treatment beyond progression to first-line therapy in melanoma: what choices do we have? |
4:30 p.m. – 4:40 p.m. |
Discussion / Q&A |
Module: NMSC Chairs: Luis Fernando Tovo and David Muniz |
|
4:40 p.m. – 4:55 p.m. |
Current indications of systemic therapies in SCC |
4:55 p.m. – 5:10 p.m. |
Treatment algorithms for patients with high-risk BCC |
5:10 p.m. – 5:30 p.m. |
Roundtable - Merkel cell carcinoma - What is the optimal treatment for patients with MCC with and without nodal involvement? |
5:30 p.m. – 5:45 p.m. |
Merkel cell carcinoma - Advances in systemic treatments over the past years |
5:45 p.m. – 6:00 p.m. |
Cutaneous lymphomas - Initial approach and what to avoid? |
6:00 p.m. – 6:10 p.m. |
Discussion / Q&A |
6:10 p.m. |
Closure |
Program – March, 12th (Saturday)
Schedule subject to change and speakers confirmations |
|
Module: MTD sessions |
|
8:30 a.m. – 8:45 a.m. |
Ophthalmology: when to suspect and how to diagnose ocular malignancies? |
8:45 a.m. – 9:00 a.m. |
Endocrinology: Vitamin D, sun exposure and skin cancers – myths and facts |
9:00 a.m. – 9:15 a.m. |
Geriatric medicine: geriatric assessment in the treatment of patients with skin cancer – weighing risks and benefits in the elderly population? |
9:15 a.m. – 9:30 a.m. |
Debate: will AI replace the dermatologist? Yes vs No |
9:30 a.m. – 9:45 a.m. |
Discussion / Q&A |
9:45 a.m. – 10:30 a.m. |
Satellite Symposium BMS* |
Plenary session – Day 2 |
|
10:30 a.m. – 10:50 a.m. |
Plenary 4 - Surgery with microscopically controlled margins – current status in melanoma, BCC and SCC |
10:50 a.m.– 11:10 a.m. |
Plenary 5 - Tackling the microbiome: where are we? |
11:10 a.m. – 11:30 a.m. |
Plenary 6 - Alternatives beyond steroids in cutaneous immune-related adverse events |
11:30 a.m. – 11:40 a.m. |
Roundtable and Q&A |
11:40 a.m. – 12:25 p.m. |
Satellite Symposium SANOFI |
Module: Approach to the immunocompromised patient |
|
12:25 p.m. – 12:45 p.m. |
Roundtable: Approach high-risk keratinocyte carcinomas in the immunocompromised patient |
12:45 p.m. – 1:00 p.m. |
Dermatologic monitoring and follow of the immunocompromised patient |
1:00 p.m. – 1:15 p.m. |
Systemic therapies in immunocompromised patients and transplant recipients |
1:15 p.m. – 1:25 p.m. |
Discussion / Q&A |
1:25 p.m. - 1:30 p.m. |
Closure |